RESPIRATORY AND INFLAMMATION (R&I) MEDICINES
WE AIM TO BUILD ON OUR STRONG POSITION IN ASTHMA TREATMENT THROUGH THE GROWTH OF KEY PRODUCTS, PARTICULARLY SYMBICORT, NEW INDICATIONS AND MARKET LAUNCHES AND THE SUCCESSFUL INTRODUCTION OF NOVEL APPROACHES TO OTHER AREAS OF INFLAMMATORY DISEASE SUCH AS SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND RHEUMATOLOGY.
2007 IN BRIEF
- Symbicort sales of $1.6 billion, up 22%.
- Symbicort pMDI for long-term maintenance treatment of asthma launched in the US to specialists and primary care physicians.
- Outside the US, Symbicort SMART now launched in over 40 countries.
- Pulmicort continued to grow with sales of over $1 billion, up 10%.
- Acquisition of MedImmune strengthened the R&I portfolio.
- Acquisition of Verus Pharmaceuticals’ paediatric asthma business in North America.
- European Patent Office revoked the European combination patent for Symbicort for use in asthma. Other patent property and data exclusivity for Symbicort not affected by the decision.
MARKETED PRODUCTS
Symbicort Turbuhaler (budesonide/formoterol in a dry powder inhaler) is a combination of an inhaled corticosteroid and a fast onset, long-acting bronchodilator for the treatment of asthma and COPD. Symbicort Turbuhaler is also available as Symbicort SMART.
Symbicort pMDI (budesonide/formoterol in a pressurised metered-dose inhaler) for the treatment of asthma.
Pulmicort (budesonide) is a corticosteroid anti-inflammatory inhalation drug that helps prevent symptoms and improves the control of asthma.
Pulmicort Respules (budesonide inhalation suspension) is the first and only nebulised corticosteroid in the US for the treatment of asthma in children as young as 12 months.
Rhinocort (budesonide) is a nasal steroid treatment for allergic rhinitis (hay fever), perennial rhinitis and nasal polyps.
Oxis (formoterol) is a fast onset, long-acting beta-agonist therapy for treating asthma and COPD.
Accolate (zafirlukast) is an oral leukotriene receptor antagonist for the treatment of asthma.
